Research programme: juvenile Batten disease therapeutics - Evotec/Beyond Batten Disease Foundation
Latest Information Update: 29 Oct 2015
At a glance
- Originator Nonindustrial sources
- Developer Beyond Batten Disease Foundation; Evotec AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neuronal ceroid lipofuscinosis
Most Recent Events
- 20 Oct 2015 Early research in Neuronal ceroid lipofuscinosis in Germany (unspecified route)